 NEW YORK and LONDON, May 05, 2021 GLOBE NEWSWIRE -- Tiziana Life Sciences plc Nasdaq: TLSA LSE: TILS Tiziana or the Company, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with Takanawa Japan K.K, Pharma Team, Takanawa for a strategic business development plan to Identify a clinical partner in Japan and other Asian countries for further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma HCC patients. HCC is the most common type of liver cancer and affects approximately 200,000 people per year. 